Search

A dose of 2.5 g of gamma-hydroxybutyric acid (GHB) was administered intravenously to 6 healthy male volunteers. A significant increase in plasma GH was observed at 30, 45, 60 and 90 min after injection. The plasma prolactin level increased significantly at 45 and 60 min after GHB injection. These responses were not found after the saline vehicle injection in the same subjects. It is conceivable that GHB could modify the release of serotonin from the nerve terminals and then stimulate the release of GH and prolactin.

Gentled rats injected subcutaneously with glucagon (20 microgram/100 g body weight) showed a significant decrease in plasma growth hormone (GH) at 15 min after glucagon injection. A subcutaneous injection of 50% glucose did not cause the early suppression as shown at 15 min after glucagon injection, but at 30 min after glucose injection a tendency to decrease in plasma GH was observed. In urethane anesthetized rats, a subcutaneous administration of glucagon (1 microgram or 10 microgram/100 g body weight) failed to elicit an increase in plasma GH. In vitro incubation of anterior pituitary fragments with glucagon failed to decrease the release of GH, suggesting that glucagon does not act directly on the anterior pituitary.

Healthy male volunteers injected subcutaneously with 200 mg L-GABOB showed no significant changes in plasma GH, prolactin and cortisol levels. On the other hand, an intrathecal injection of 300 mg D, L-GABOB to cerebrovascular patients caused significant increases in plasma GH, prolactin and cortisol levels at 60 min after injection. These results indicate that GABOB may elicit the secretion of GH, prolactin and ACTH via the central nervous system.

gamma-Aminobutyric acid (GABA; 50 or 500 microgram/10 microliter) was injected into the right lateral ventricle of urethane- or pentobarbital-anesthetized male rats. The animals were decapitated 15 min after injection. Serum GH and hypothalamic somatostatin (SRIF) concentration were measured by specific RIAs. Intraventricular GABA caused a dose-related increase in GH and SRIF. In another study, aminooxyacetic acid (5 or 20 mg) was injected ip into urethane-anesthetized rats. Aminooxyacetic acid at 20 mg produced a significant increase in both serum GH and hypothalamic SRIF. Furthermore, 12.5 mg gamma-hydroxybutyric acid (GHB) injected ip into urethane- or pentobarbital-anesthetized rats elicited a significant increase in both serum GH and hypothalamic SRIF. Pretreatment with 20 mg L-dopa produced decreases in the GHB-induced serum GH increase and in hypothalamic SRIF in pentobarbital-anesthetized rats. These results show that GABA and GHB stimulated GH secretion, which was accompanied by increased hypothalamic SRIF. Thus, the GH release induced by GABA or GHB may be partly involved in inhibiting the release of hypothalamic SRIF. As the GHB-induced GH release was inhibited by L-dopa, the stimulatory effect of GHB on GH secretion might be mediated by inhibition of the dopaminergic mechanism.